C/CPublished research associates this genotype with typical/baseline likelihood of Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio) — no copies of the reported risk allele. (GWAS Catalog, Hum Mol Genet 2016, PMID:27702941)
C/TPublished research associates this genotype (one copy of the reported risk allele) with an intermediate association with Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio). (GWAS Catalog, Hum Mol Genet 2016, PMID:27702941)
T/TPublished research associates this genotype (two copies of the reported risk allele) with a higher likelihood of Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio) compared to the general population. (GWAS Catalog, Hum Mol Genet 2016, PMID:27702941)
rs66500423 is a single position in the genome, in or near the CYP2A6 gene. Published research associates it with caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio). A single variant does not decide an outcome — it shifts a probability, and for most common variants the shift is small.
Does rs66500423 affect how medicines work?
CYP2A6 carries pharmacogenomic findings for Smoking cessation medicines. That is educational information, not a prescription or a dosing guide. Any decision to start, stop or change a medicine belongs with the clinician or pharmacist managing your treatment.
Does having rs66500423 mean I will get this?
No. Common variants like this one move a probability slightly and, on their own, rarely decide anything about one person. Nothing on this page is a diagnosis, and health decisions should be made with a clinician who can see your whole picture.
Where does the information about rs66500423 come from?
GWAS Catalog, Hum Mol Genet 2016, PMID:27702941. Every variant on MyGeneLog comes from public primary sources and is published with its citation and the date it was checked.